101 related articles for article (PubMed ID: 29080080)
41. Ubiquitin C-terminal hydrolase L1 (UCHL1), a double-edged sword in mammalian oocyte maturation and spermatogenesis.
Yang D; Lu Q; Peng S; Hua J
Cell Prolif; 2023 Feb; 56(2):e13347. PubMed ID: 36218038
[TBL] [Abstract][Full Text] [Related]
42. Programmed Cell Death in Diabetic Nephropathy: A Review of Apoptosis, Autophagy, and Necroptosis.
Erekat NS
Med Sci Monit; 2022 Aug; 28():e937766. PubMed ID: 35989481
[TBL] [Abstract][Full Text] [Related]
43. Research Progress of DUB Enzyme in Hepatocellular Carcinoma.
Zhao J; Guo J; Wang Y; Ma Q; Shi Y; Cheng F; Lu Q; Fu W; Ouyang G; Zhang J; Xu Q; Hu X
Front Oncol; 2022; 12():920287. PubMed ID: 35875077
[TBL] [Abstract][Full Text] [Related]
44. Inhibiting UCH-L5: Rational Design of a Cyclic Ubiquitin-Based Peptide Inhibitor.
Hameed DS; Ovaa H; van der Heden van Noort GJ; Sapmaz A
Front Mol Biosci; 2022; 9():866467. PubMed ID: 35720124
[TBL] [Abstract][Full Text] [Related]
45.
Zhang Q; Liu YJ; Li JP; Zeng SH; Shen H; Han M; Guo S; Liu SL; Zou X
J Inflamm Res; 2022; 15():3065-3082. PubMed ID: 35637872
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of autoantibodies combined with tumor markers in the detection of lung cancer.
Mu Y; Li J; Xie F; Xu L; Xu G
J Clin Lab Anal; 2022 Aug; 36(8):e24504. PubMed ID: 35596744
[TBL] [Abstract][Full Text] [Related]
47. Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients.
Schwarzenbach H; Gahan PB
Cancer Drug Resist; 2019; 2(2):271-296. PubMed ID: 35582723
[TBL] [Abstract][Full Text] [Related]
48. Predictive value of exosomes and their cargo in drug response/resistance of breast cancer patients.
Schwarzenbach H; Gahan PB
Cancer Drug Resist; 2020; 3(1):63-82. PubMed ID: 35582044
[TBL] [Abstract][Full Text] [Related]
49. UCHL1 acts as a potential oncogene and affects sensitivity of common anti-tumor drugs in lung adenocarcinoma.
Yao J; Reyimu A; Sun A; Duoji Z; Zhou W; Liang S; Hu S; Wang X; Dai J; Xu X
World J Surg Oncol; 2022 May; 20(1):153. PubMed ID: 35546675
[TBL] [Abstract][Full Text] [Related]
50. UCHL5 controls β-catenin destruction complex function through Axin1 regulation.
Han W; Koo Y; Chaieb L; Keum BR; Han JK
Sci Rep; 2022 Mar; 12(1):3687. PubMed ID: 35256667
[TBL] [Abstract][Full Text] [Related]
51. Imaging-Based Screening of Deubiquitinating Proteases Identifies Otubain-1 as a Stabilizer of c-MYC.
Moree SE; Maneix L; Iakova P; Stossi F; Sahin E; Catic A
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159073
[TBL] [Abstract][Full Text] [Related]
52. Parathyroid Carcinoma and Adenoma Co-existing in One Patient: Case Report and Comparative Proteomic Analysis.
Ciregia F; Cetani F; Pardi E; Soggiu A; Piras C; Zallocco L; Borsari S; Ronci M; Caruso V; Marcocci C; Mazzoni MR; Lucacchini A; Giusti L
Cancer Genomics Proteomics; 2021; 18(6):781-796. PubMed ID: 34697069
[TBL] [Abstract][Full Text] [Related]
53. Small-Molecule Inhibitors Targeting Proteasome-Associated Deubiquitinases.
Moon S; Muniyappan S; Lee SB; Lee BH
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207520
[TBL] [Abstract][Full Text] [Related]
54. Ubiquitin Carboxyl-Terminal Hydrolases and Human Malignancies: The Novel Prognostic and Therapeutic Implications for Head and Neck Cancer.
Rong C; Zhou R; Wan S; Su D; Wang SL; Hess J
Front Oncol; 2020; 10():592501. PubMed ID: 33585209
[TBL] [Abstract][Full Text] [Related]
55. UCHL3 promotes proliferation of colorectal cancer cells by regulating SOX12 via AKT/mTOR signaling pathway.
Li J; Zheng Y; Li X; Dong X; Chen W; Guan Z; Zhang C
Am J Transl Res; 2020; 12(10):6445-6454. PubMed ID: 33194042
[TBL] [Abstract][Full Text] [Related]
56. Deubiquitination Reactions on the Proteasome for Proteasome Versatility.
Shin JY; Muniyappan S; Tran NN; Park H; Lee SB; Lee BH
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32726943
[TBL] [Abstract][Full Text] [Related]
57. The Role of Deubiquitinating Enzymes in Acute Lung Injury and Acute Respiratory Distress Syndrome.
Li T; Zou C
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32650621
[TBL] [Abstract][Full Text] [Related]
58. Ubiquitin-proteasome system-targeted therapy for uveal melanoma: what is the evidence?
Zhao CX; Zeng CM; Wang K; He QJ; Yang B; Zhou FF; Zhu H
Acta Pharmacol Sin; 2021 Feb; 42(2):179-188. PubMed ID: 32601365
[TBL] [Abstract][Full Text] [Related]
59. BAP1 functions as a tumor promoter in prostate cancer cells through EMT regulation.
Park CM; Lee JE; Kim JH
Genet Mol Biol; 2020; 43(2):e20190328. PubMed ID: 32422649
[TBL] [Abstract][Full Text] [Related]
60. LncRNA DRAIC inhibits proliferation and metastasis of gastric cancer cells through interfering with NFRKB deubiquitination mediated by UCHL5.
Zhang Z; Hu X; Kuang J; Liao J; Yuan Q
Cell Mol Biol Lett; 2020; 25():29. PubMed ID: 32351584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
